Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 8.30% is 19% below its 5-year average of 10.21%, around the middle of its 5-year range (-4.62%–18.04%).
25.40% below its 12-month average of 11.13%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 17.04%.
EBITDA MARGIN
8.30%
EBITDA MARGIN AVG TTM
11.13%
EBITDA MARGIN AVG 3Y
9.35%
EBITDA MARGIN AVG 5Y
10.21%
EBITDA MARGIN AVG 10Y
10.94%
EBITDA MARGIN AVG 15Y
11.87%
EBITDA MARGIN AVG 20Y
11.16%
CURRENT VS TTM AVG
-25.40%
CURRENT VS 3Y AVG
-11.19%
CURRENT VS 5Y AVG
-18.72%
CURRENT VS 10Y AVG
-24.11%
CURRENT VS 15Y AVG
-30.10%
CURRENT VS 20Y AVG
-25.61%
Market Cap
$1.61B
EBITDA Margin
-172.34%
TTM Avg
-3780.22%
3Y Avg
-1874.89%
5Y Avg
-1874.89%
Market Cap
$1.61B
EBITDA Margin
-512.70%
TTM Avg
-388.17%
3Y Avg
-265.21%
5Y Avg
-263.30%
Market Cap
$1.62B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
Market Cap
$1.60B
EBITDA Margin
-1075.09%
TTM Avg
-854.02%
3Y Avg
-886.21%
5Y Avg
-631.69%
Market Cap
$1.63B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
Market Cap
$1.59B
EBITDA Margin
-164.52%
TTM Avg
-214.39%
3Y Avg
-473.06%
5Y Avg
-473.06%
Market Cap
$1.57B
EBITDA Margin
-10.20%
TTM Avg
-140.78%
3Y Avg
-597.36%
5Y Avg
-597.36%
Market Cap
$1.54B
EBITDA Margin
-158.44%
TTM Avg
-796.42%
3Y Avg
-796.42%
5Y Avg
-1562.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omnicell, Inc. (OMCL) | $1.61B | 8.30% | 11.13% | 9.35% | 10.21% |
| Septerna Inc (SEPN)vs › | $1.61B | -172.34% | -3780.22% | -1874.89% | -1874.89% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -512.70% | -388.17% | -265.21% | -263.30% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 0.06% | -4.29% | -15.38% | -22.40% |
| uniQure N.V. (QURE)vs › | $1.60B | -1075.09% | -854.02% | -886.21% | -631.69% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 19.54% | 15.33% | 15.07% | 12.91% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -164.52% | -214.39% | -473.06% | -473.06% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -10.20% | -140.78% | -597.36% | -597.36% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -158.44% | -796.42% | -796.42% | -1562.06% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 47.98% | 50.86% | 52.39% | 67.36% |
Gross Margin
44.8%
EBITDA Margin
8.3%
Operating Margin
4.7%
Net Margin
3.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 17.04% |
| 2026-03-31 | 11.43% |
| 2025-12-31 | 7.39% |
| 2025-09-30 | 9.53% |
| 2025-06-30 | 10.24% |
| 2025-03-31 | 3.79% |
| 2024-12-31 | 11.72% |
| 2024-09-30 | 10.18% |
| 2024-06-30 | 9.40% |
| 2024-03-31 | 1.83% |
| 2023-12-31 | 0.14% |
| 2023-09-30 | 9.13% |
| 2023-06-30 | 10.64% |
| 2023-03-31 | 0.43% |
| 2022-12-31 | -4.62% |
| 2022-09-30 | 12.41% |
| 2022-06-30 | 11.43% |
| 2022-03-31 | 9.26% |
| 2021-12-31 | 11.13% |
| 2021-09-30 | 17.05% |
| 2021-06-30 | 18.04% |
| 2021-03-31 | 15.91% |
| 2020-12-31 | 16.14% |
| 2020-09-30 | 13.01% |
| 2020-06-30 | 5.12% |
| 2020-03-31 | 12.57% |
| 2019-12-31 | 15.65% |
| 2019-09-30 | 17.91% |
| 2019-06-30 | 15.93% |
| 2019-03-31 | 13.83% |
| 2018-12-31 | 15.49% |
| 2018-09-30 | 14.76% |
| 2018-06-30 | 10.52% |
| 2018-03-31 | 7.09% |
| 2017-12-31 | 14.47% |
| 2017-09-30 | 11.95% |
| 2017-06-30 | 6.13% |
| 2017-03-31 | -3.18% |
| 2016-12-31 | 8.30% |
| 2016-09-30 | 11.11% |
| 2016-06-30 | 8.45% |
| 2016-03-31 | 9.55% |
| 2015-12-31 | 14.70% |
| 2015-09-30 | 16.24% |
| 2015-06-30 | 16.57% |
| 2015-03-31 | 13.84% |
| 2014-12-31 | 15.67% |
| 2014-09-30 | 16.80% |
| 2014-06-30 | 16.50% |
| 2014-03-31 | 14.31% |
| 2013-12-31 | 14.83% |
| 2013-09-30 | 16.17% |
| 2013-06-30 | 15.08% |
| 2013-03-31 | 9.92% |
| 2012-12-31 | 15.38% |
| 2012-09-30 | 17.95% |
| 2012-06-30 | 7.20% |
| 2012-03-31 | 9.31% |
| 2011-12-31 | 13.24% |
| 2011-09-30 | 10.58% |
| 2011-06-30 | 10.12% |
| 2011-03-31 | 5.04% |
| 2010-12-31 | 6.37% |
| 2010-09-30 | 9.23% |
| 2010-06-30 | 10.37% |
| 2010-03-31 | 6.71% |
| 2009-12-31 | 6.65% |
| 2009-09-30 | 6.01% |
| 2009-06-30 | 7.06% |
| 2009-03-31 | -0.95% |
| 2008-12-31 | 9.93% |
| 2008-09-30 | 9.76% |
| 2008-06-30 | 10.84% |
| 2008-03-31 | 11.24% |
| 2007-12-31 | 12.45% |
| 2007-09-30 | 11.20% |
| 2007-06-30 | 9.78% |
| 2007-03-31 | 9.07% |
| 2006-12-31 | 12.44% |
| 2006-09-30 | 8.55% |
| 2006-06-30 | 7.02% |
| 2006-03-31 | 5.68% |
| 2005-12-31 | 8.72% |
| 2005-09-30 | 7.61% |
| 2005-06-30 | 3.62% |
| 2005-03-31 | -16.67% |
| 2004-12-31 | 10.53% |
| 2004-09-30 | 13.12% |
| 2004-06-30 | 11.68% |
| 2004-03-31 | 11.96% |
| 2003-12-31 | 12.86% |
| 2003-09-30 | 12.61% |
| 2003-06-30 | 9.42% |
| 2003-03-31 | 5.10% |
| 2002-12-31 | -29.32% |
| 2002-09-30 | -10.62% |
